FindTrial
Sign In

Utility of Epalrestat in Diabetic Symmetrical Peripheral Neuropathy

Erythrocyte Sorbitol Levels as Predictor of Response to Epalrestat in Diabetic Symmetrical Peripheral Neuropathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011527
Enrollment
100
Registered
2018-01-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Diabetic Patients with Peripheral Neuropathy

Interventions

None listed

Sponsors

Department of Endocrinology and Metabolism
Lead Sponsor
Dr Rujul Jain
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Diabetes of more than 5 years duration Diabetic Neuropathy Symptom Score more than or equal to one Vibration Potential Threshold more than 25 millivolt

Exclusion criteria

Exclusion criteria: Diabetes of less than 5 years duration Patients having active foot ulcer Patients on drugs which might affect Peripheral Neuropathy and Sorbitol levels Chronic Alcoholic consumption Patients with Vitamin B12 deficiency

Design outcomes

Primary

MeasureTime frame
To evaluate Erythrocyte Sorbitol Levels as predictor of therapeutic response to Epalrestat in the management of Diabetic Symmetrical Peripheral NeuropathyTimepoint: Patients will be recruited and followed up for 3 months—

Secondary

MeasureTime frame
To evaluate effect of Glycemic control on Sorbitol levelsTimepoint: Patients will be recruited and followed up for 3 months—

Countries

India

Contacts

Public ContactDr Rujul Jain

Institute of Medical Sciences Banaras Hindu University Varanasi

sksendocrine@yahoo.com9415203534

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026